secwatch / observer
8-K filed May 15, 2023, 7:59 PM ET ticker EW CIK 0001099800
leadership confidence high sentiment neutral materiality 0.35

Edwards Lifesciences raises CEO Zovighian's base salary to $1.05M; shareholders approve officer exculpation

Edwards Lifesciences Corp

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

Edwards Lifesciences Corp: Amendment to Certificate of Incorporation to provide for exculpation of officers as permitted by the Delaware General Corporation Law (effective 2023-05-12).

Change
charter amendment
Effective
2023-05-12
Exact text from the filing
On May 11, 2023, the Company held its 2023 Annual Meeting of Stockholders (the “Annual Meeting”), at which stockholders approved an amendment (the “Amendment”) to the Company’s Amended and Restated Certificate of Incorporation to provide for exculpation of officers as permitted by the Delaware General Corporation Law. The Amendment became effective immediately upon filing with the Secretary of State of the State of Delaware on May 12, 2023.
View on SEC.gov
Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Edwards Lifesciences Corp shareholders approved Proposal 2: Advisory vote on named executive officer compensation at the 2023-05-11 meeting.

Proposal
say on pay
Outcome
passed
Meeting
2023-05-11
Exact text from the filing
The advisory proposal regarding the Company’s named executive officer compensation was approved
View on SEC.gov
Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Edwards Lifesciences Corp shareholders rejected Proposal 6: Stockholder proposal regarding independent board chairman policy at the 2023-05-11 meeting.

Outcome
failed
Meeting
2023-05-11
Exact text from the filing
The stockholder proposal regarding an independent board chairman policy was not approved
View on SEC.gov
Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Edwards Lifesciences Corp shareholders approved Proposal 5: Amendment to Certificate of Incorporation for officer exculpation at the 2023-05-11 meeting.

Proposal
charter amendment
Outcome
passed
Meeting
2023-05-11
Exact text from the filing
The amendment of the Company’s Certificate of Incorporation to provide for exculpation of officers as permitted by the Delaware General Corporation Law was approved
View on SEC.gov
Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Edwards Lifesciences Corp shareholders approved Proposal 1: Election of Directors at the 2023-05-11 meeting.

Proposal
director election
Outcome
passed
Meeting
2023-05-11
Exact text from the filing
All the nominees for director listed in Proposal 1 were elected to serve until the Company’s next annual meeting of stockholders and until their respective successors are duly elected and qualified
View on SEC.gov
Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Edwards Lifesciences Corp shareholders approved Proposal 4: Ratification of PricewaterhouseCoopers LLP as independent auditor for 2023 at the 2023-05-11 meeting.

Proposal
auditor ratification
Outcome
passed
Meeting
2023-05-11
Exact text from the filing
Ratification of the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023 was approved
View on SEC.gov
Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Edwards Lifesciences Corp shareholders approved Proposal 3: Advisory vote on frequency of future say-on-pay votes at the 2023-05-11 meeting.

Proposal
say on pay frequency
Outcome
passed
Meeting
2023-05-11
Exact text from the filing
The advisory proposal regarding the frequency of advisory votes on named executive officer compensation was approved with one year as the preferred frequency
View on SEC.gov

Browse all governance changes →

Edwards Lifesciences Corp filing history →

Source: SEC EDGAR
accession 0001193125-23-144564
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.